Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model

Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model

# Objectives To estimate the public health impact of annual vaccination of children with a quadrivalent live-attenuated influenza vaccine (QLAIV) across Europe. # Methods A deterministic, age-structured, dynamic model was used to simulate influenza transmission across 14 European countries, compari...

Full description

Saved in:

Bibliographic Details
Main Authors:	Laetitia Gerlier, Judith Hackett, Richard Lawson, Sofia Dos Santos Mendes, Catherine Weil-Olivier, Markus Schwehm, Martin Eichner
Format:	Article
Language:	English
Published:	Columbia Data Analytics, LLC 2017-07-01
Series:	Journal of Health Economics and Outcomes Research
Online Access:	https://doi.org/10.36469/9801
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Translation of the UK Pediatric Influenza Vaccination Programme in Primary Schools to 13 European Countries Using a Dynamic Transmission Model
by: Laetitia Gerlier, et al.
Published: (2017-08-01)

Assessment of Reactogenicity and Immunogenicity of the Quadrivalent Live Attenuated Influenza Vaccine
by: D. A. Lioznov, et al.
Published: (2018-06-01)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
by: Eliel Nham, et al.
Published: (2023-12-01)

The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines
by: S. M. Kharit, et al.
Published: (2017-06-01)

Evaluation of determinants of the serological response to the quadrivalent split‐inactivated influenza vaccine
by: Shaohuan Wu, et al.
Published: (2022-05-01)

End of season 2022/2023 quadrivalent influenza vaccine effectiveness in preventing influenza in primary care in Portugal
by: Irina Kislaya, et al.
Published: (2023-12-01)

Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea
by: Youngji Song, et al.
Published: (2024-12-01)

On Approval of the Plan for a Phased Transition to the Use of Quadrivalent Vaccines for the Prevention of Influenza
by: article Editorial
Published: (2019-03-01)

INFLUENZA VACCINATION OF CHILDREN OF PRESCHOOL AGE IN THE RUSSIAN FEDERATION: COST-EFFECTIVENESS OF QUADRIVALENT VACCINE
by: A. V. Rudakova, et al.
Published: (2019-03-01)

Maintaining the value of influenza vaccination – the shift from quadrivalent to trivalent vaccines: an expert review
by: David Fisman, et al.
Published: (2025-12-01)

Optimization for the production of a dengue live-attenuated Quadrivalent vaccine in Vero cells grown on microcarriers
by: Shannon Haughney, et al.
Published: (2025-06-01)

Evaluation of the Epidemiological Effectiveness of a Quadrivalent Inactivated Split Influenza Vaccine in the 2023–2024 flu season
by: R. V. Polibin, et al.
Published: (2025-01-01)

Evaluation of Humoral and Cell-Mediated Immunity Induced by Quadrivalent Influenza Vaccine in Pre-COVID-19 Japan
by: Naruhito Otani, et al.
Published: (2025-04-01)

« J’ai donné une âme à Winnetou » Interview avec l’acteur Pierre Brice sur le rôle de sa vie
by: Olivier Schwehm
Published: (2015-07-01)

Passive enhanced safety surveillance of GSK’s quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season
by: Gaël Dos Santos, et al.
Published: (2019-08-01)

The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
by: Wanqin Tang, et al.
Published: (2025-08-01)

Safety and Influenza Infections in Children Aged 6–35 Months Receiving Cell Culture-Derived Inactivated Quadrivalent Influenza Vaccine During the 2023–2024 Influenza Season in South Korea
by: Hye Eun Lee, et al.
Published: (2025-05-01)

Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories
by: Feng Wen, et al.
Published: (2025-12-01)

Correction: The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
by: Frontiers Production Office
Published: (2025-08-01)

Investigation of Influenza A(H5N1) Virus Neutralization by Quadrivalent Seasonal Vaccines, United Kingdom, 2021–2024
by: Phoebe Stevenson-Leggett, et al.
Published: (2025-06-01)

Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season
by: Marina Amaral de Avila Machado, et al.
Published: (2024-12-01)

An overview of the meningococcal disease and impact of the quadrivalent meningococcal conjugate vaccine
by: Asmaa Alrobai, et al.
Published: (2021-12-01)

Cost-effectiveness of quadrivalent human papillomavirus vaccination in adolescent girls
by: A. V. Rudakova, et al.
Published: (2016-11-01)

Results of a clinical study of the influenza tetravalent inactivated subunit adjuvant vaccine Grippol Quadrivalent in children aged 6 months to 5 years (inclusive)
by: Viktor V. Romanenko, et al.
Published: (2024-07-01)

Immunogenicity and safety of concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine in Chinese adults: An open-label, randomized, controlled trial
by: Tao Huang, et al.
Published: (2024-12-01)

Immunogenicity and Antibody Persistence of the Inactivated Quadrivalent Influenza Vaccine in Pediatric Patients Post-Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation Versus Healthy Controls
by: Mi Yeon Hur, et al.
Published: (2024-10-01)

Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6–35 months of age in China: A randomized, double-blind, clinical trial
by: Shilei Wang, et al.
Published: (2024-12-01)

Indirect Transmission of Influenza A Virus between Pig Populations under Two Different Biosecurity Settings.
by: Matt W Allerson, et al.
Published: (2013-01-01)

Disparities in Seasonal Influenza Vaccination in Europe
by: Katinka M. Giezeman‐Smits, et al.
Published: (2025-07-01)

The Effectiveness of Four Quadrivalent, Inactivated Influenza Vaccines Administered Alone or in Combination with Pneumococcal and/or SARS-CoV-2 Vaccines: A Population-Wide Cohort Study
by: Cecilia Acuti Martellucci, et al.
Published: (2025-03-01)

Prevention of Cardiovascular Diseases with Standard-Dose Quadrivalent Influenza Vaccine in People Aged ≥50 Years in Australia During the 2017 A/H3N2 Epidemic
by: Zubair Akhtar, et al.
Published: (2025-04-01)

Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Adolescent Girls in Russian Federation
by: Alla V. Rudakova, et al.
Published: (2018-01-01)

Adapt to Survive? Attenuating Indirect Effects of Career Adaptability on Exhaustion via Career Insecurity
by: Daniel Spurk, et al.
Published: (2025-06-01)

The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial
by: Lili Huang, et al.
Published: (2025-04-01)

FIRST APPLICATION EXPERIENCE OF THE QUADRIVALENT VACCINE FOR PREVENTION OF THE PAPILLOMA VIRAL INFECTION AND CERVICAL CANCER
by: M.G. Galitskaya, et al.
Published: (2008-07-01)

A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT)
by: Ener Cagri Dinleyici, et al.
Published: (2025-12-01)

GARDASIL. QUADRIVALENT RECOMBINANT VACCINE AGAINST HPV (6, 11, 16, 18 TYPES)
by: article editorial
Published: (2007-04-01)

Predictors of parental acceptance to live attenuated influenza vaccine for children
by: Shujuan Qu, et al.
Published: (2024-12-01)

Absenteeism and Productivity Loss Due to Influenza or Influenza-like Illness in Adults in Europe and North America
by: David Fisman, et al.
Published: (2024-12-01)

No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial
by: Abdi Naficy, et al.
Published: (2024-12-01)